Form 4: Guardant Health Director Krognes Acquires Shares

Guardant Health Director Steve E. Krognes reported the acquisition of 155 shares of common stock through the vesting of restricted stock units.

Summary

• Steve E. Krognes, a Director of Guardant Health, Inc. (GH), acquired 155 shares of common stock.
• The acquisition occurred on March 31, 2026, through the vesting of restricted stock units (RSUs).
• The transaction price for the acquired common stock was $0 per share.
• Following this transaction, Steve E. Krognes directly beneficially owns 19,208 shares of Guardant Health common stock.
• Concurrently, 155 derivative securities (Restricted Stock Units) were disposed of due to their conversion into common stock.
• After the transaction, Steve E. Krognes directly beneficially owns 463 Restricted Stock Units.
• The Restricted Stock Unit award was originally granted on August 9, 2022, with a four-year vesting schedule.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a slightly positive event. While a routine compensation event, it increases insider ownership, which generally aligns management's interests with shareholders.

Positives

• The transaction represents an increase in direct beneficial ownership of common stock by a company director, aligning management interests with shareholders.
• The acquisition of shares through RSU vesting indicates a director's continued stake in the company's future performance.

Future Outlook

The remaining 75% of the Restricted Stock Unit award, granted on August 9, 2022, vests in substantially equal monthly installments over the three-year period following June 30, 2023, indicating future scheduled share acquisitions by the director.

Industry Context

StockSavvy.ai notes that routine insider transactions, such as the vesting of restricted stock units, are common occurrences in publicly traded companies. These events reflect pre-scheduled compensation arrangements and generally do not signal new strategic shifts or immediate market-moving information, unlike open market purchases or sales.

Comparison to Industry Standards

• The vesting schedule of 4 years for RSUs is a common practice in the biotechnology and healthcare sectors, aligning executive compensation with long-term company performance.
• The acquisition of shares at a $0 exercise price is typical for RSU vesting, as these awards represent a grant of shares rather than an option to purchase at a set price.

Related Party Transactions

• The transaction involves a company director, Steve E. Krognes, acquiring shares from the issuer, Guardant Health, Inc., through a pre-existing compensation plan (Restricted Stock Units).

Stakeholder Impact

• Shareholders: Increased transparency regarding insider holdings and a slight increase in director ownership, potentially signaling confidence in the company's long-term prospects.
• Employees: The RSU vesting structure is a common form of equity compensation, impacting employee retention and motivation for those with similar awards.

Next Steps

• Continued vesting of the remaining 463 Restricted Stock Units in substantially equal monthly installments over the period following June 30, 2023.

Key Dates

Keywords

Guardant Health, GH, Steve Krognes, Insider Transaction, Form 4, Restricted Stock Units, RSU Vesting, Director Ownership, Common Stock